IN THE CLAIMS

Please cancel claims 1, 7, 14, 16, 19, 21, 27 to 29, and 62 to 64 without prejudice.

Please amend the claims as follows:

1. (Canceled) ~~A human monoclonal antibody or fragment thereof that specifically binds to human CD40.~~

3. (Amended) A [The] human monoclonal antibody or fragment thereof [of claim 1], wherein the antibody is [produced by a hybridoma cell line or subclones thereof, and wherein the antibody is] denoted [as no.] number 11 or 72(produced by hybridomas ATCC PTA-2308 and PTA-2309, respectively), or [the] produced by a hybridoma [is] denoted as F1-102 (ATCC PTA-3337), or F4-465 (ATCC PTA-3338) [F5-152], or denoted as F2-103 (ATCC PTA-3302 and PTA-3303, heavy and light chain, respectively), F5-77 (ATCC PTA-3304 and PTA-3305, heavy and light chain, respectively), or F5-157 (ATCC PTA-3306 and PTA-3307, heavy and light chain, respectively) [or F4-465].

4. (Amended) A [The] human monoclonal antibody or fragment thereof [of claim 1], wherein the antibody has the CD40 binding specificity of the antibody denoted as [no.] number 11 or 72 (produced by hybridomas ATCC PTA-2308 and PTA-2309, respectively), or [the antibody] produced by [the] a hybridoma denoted as F1-102 (ATCC PTA-3337), or F4-465 (ATCC PTA-3338) [F5-152], or denoted as F2-103 (ATCC PTA-3302 and PTA-3303, heavy and light chain, respectively), F5-77 (ATCC PTA-3304 and PTA-3305, heavy and light chain, respectively), or F5-157 (ATCC PTA-3306 and PTA-3307, heavy and light chain, respectively) [or F4-465].

5. (Amended) A [The] human monoclonal antibody or fragment thereof [of claim 1], wherein the antibody has a CD40 modulating activity of the antibody denoted as [no.] number 11 or 72 (produced by hybridomas ATCC PTA-2308 and PTA-2309, respectively), or [the antibody] produced by [the] a hybridoma denoted as F1-102 (ATCC PTA-3337), or F4-465 (ATCC PTA-3338) [F5-152], or denoted as F2-103 (ATCC PTA-3302 and PTA-3303, heavy and light chain, respectively), F5-77 (ATCC PTA-3304 and

PTA-3305, heavy and light chain, respectively), or F5-157 (ATCC PTA-3306 and PTA-3307, heavy and light chain, respectively) [or F4-465].

6. (Amended) The human monoclonal antibody fragment of [claim 1] any of claims 3 to 5, wherein the fragment comprises an scFv, Fab, Fab', or $F(ab')_2$ fragment.

7. (Canceled) ~~The human monoclonal antibody fragment of claim 6, wherein the fragment comprises a fragment of the antibody denoted as no. 11 or 72, or the antibody produced by the hybridoma denoted as F1-102, F5-152, F2-103, F5-77, F5-157 or F4-465~~.

8. (Amended) A [The] detectably labeled human monoclonal antibody [of claim 1], wherein the antibody is produced by the hybridoma or is the antibody of any of claims 3 to 5 [, wherein the antibody is detectably labeled].

10. (Amended) The human monoclonal antibody selected from the antibodies of [claim 1 any of] claims 3 to 5, wherein the antibody decreases binding of a CD40 ligand to CD40.

C.1

11. (Amended) The human monoclonal antibody selected from the antibodies of [claim 1] claims 3 to 5, wherein the antibody increases binding of a CD40 ligand to CD40.

Cont

12. (Amended) The human monoclonal antibody selected from the antibodies of [claim 1] claims 3 to 5, wherein the antibody decreases [a CD40 activity] cell surface expression of E-selectin, ICAM-1 or VCAM-1; decreases adhesion of leukocytes to inflammation sites; decreases IL-12 or nitric oxide production by macrophages; decreases cell proliferation; or decreases CD95, CD80 or CD86 protein expression.

13. The human monoclonal antibody of claim 12, wherein the antibody contains a lambda light chain sequence.

14. (Canceled) ~~The human monoclonal antibody of claim 12, wherein the antibody decreases proliferation of a cell expressing CD40~~.

15. (Amended) The human monoclonal antibody of claim [14] 12, wherein the cell is a B-cell.

16. (Canceled) ~~The human monoclonal antibody of claim 12, wherein the antibody decreases expression of a protein~~.

17. (Amended) The human monoclonal antibody of claim [16] 12, wherein the antibody decreases [protein comprises] CD95, CD80 or CD86 protein expression.

18. (Amended) The human monoclonal antibody selected from the antibodies of [claim 1] claims 3 to 5, wherein the antibody increases [a CD40 activity] cell surface expression of E-selectin, ICAM-1 or VCAM-1; increases adhesion of leukocytes to inflammation sites; increases IL-12 or nitric oxide production by macrophages; increases cell proliferation; or increases CD95, CD80 or CD86 protein expression.
19. (Canceled) ~~The human monoclonal antibody of claim 18, wherein the antibody increases proliferation of a cell expressing CD40~~.
20. (Amended) The human monoclonal antibody of claim [19] 18, wherein the cell is a B-cell.
21. (Canceled) ~~The human monoclonal antibody of claim 18, wherein the antibody increases expression of a protein~~.
22. (Amended) The human monoclonal antibody of claim [21] 18, wherein the antibody increases [protein comprises] CD95, CD80 or CD86 protein expression.
23. (Amended) The human monoclonal antibody of [claim 1] any of claims 3 to 5, further comprising a pharmaceutical formulation.
24. (Amended) A host cell that expresses the antibody of [claim 1] any of claims 3 to 5.
25. (Amended) A nucleic acid that encodes the antibody of [claim 1] any of claims 3 to 5.
26. A host cell containing the nucleic acid of claim 25.
27. (Canceled) ~~A method of producing a human CD40 antibody that modulates an activity of CD40 comprising:~~
    ~~(a) administering CD40 or an immunogenic fragment thereof to a mouse capable of expressing human immunoglobulin;~~
    ~~(b) screening the administered mouse for expression of a human CD40 antibody;~~
    ~~(c) selecting a mouse that produces a human CD40 antibody;~~
    ~~(d) isolating an antibody from the mouse that produces a human CD40 antibody; and~~
    (e) ~~determining whether the human CD40 antibody modulates an activity of CD40, thereby producing a human CD40 antibody that modulates an activity of CD40~~.

C1 Cont

28. (Canceled) ~~A method of producing a human CD40 monoclonal antibody that modulates an activity of CD40; comprising:~~

~~(a) administering human CD40 or an immunogenic fragment thereof to a mouse capable of expressing human immunoglobulin;~~

~~(b) isolating spleen cells from the mouse that produces a human CD40 antibody;~~

~~(c) fusing the spleen cells with a myeloma cell to produce a hybridoma; and screening the hybridoma for expression of a human CD40 antibody that modulates an activity of CD40, thereby producing a human monoclonal CD40 antibody that modulates an activity of CD40~~.

C1 Cont

29. (Canceled) ~~A monoclonal antibody isolated from a hybridoma produced by the method of claim 28~~.

62. (Canceled) ~~The human monoclonal antibody or fragment of claim 1, wherein the antibody inhibits CD95 expression of Ramos B cells mediated by CD40 ligand in vitro, in the condition of 1 μg/ml of soluble CD40 ligand and 1 μg/ml of the antibody~~.

63. (Canceled) ~~The human monoclonal antibody or fragment of claim 1, wherein the antibody inhibits human B-cell proliferation mediated by CD40 ligand in vitro, in the condition of 1 μg/ml of soluble CD40 ligand and 10 nanogram/ml of the antibody~~.

64. (Canceled) ~~The human monoclonal antibody or fragment of claim 62 or 63, wherein the antibody has a Kd value of 0.8 to 4 nM, as determined by BiaCore® analysis~~.

Please add the following new claims:

--65. (New) A human monoclonal antibody, wherein the antibody comprises heavy-chain variable sequence and light-chain variable sequence of the antibody selected from the antibodies denoted as number 11, 72 (produced by hybridomas ATCC PTA-2308 and PTA -2309, respectively), or produced by a hybridoma denoted as F1-102 (ATCC PTA-3337), or F4-465 (ATCC PTA-3338), or denoted as F2-103 (ATCC PTA-3302 and PTA-3303, heavy and light chain, respectively), F5-77 (ATCC PTA-3304 and PTA-3305, heavy and light chain, respectively), and F5-157 (ATCC PTA-3306 and PTA-3307, heavy and light chain, respectively).

C2

66. (New) A human monoclonal antibody, wherein the antibody comprises heavy-chain variable sequence and light-chain variable sequence encoded by the pair of sequences set forth as SEQ ID NO:10 and SEQ ID NO:11; SEQ ID NO:12 and SEQ ID NO:13; or SEQ ID NO:14 and SEQ ID NO:15.--